* Neximmune Inc NEXI.OQ NEXI.O is expected to report
results on August 9.
* Refinitiv's mean analyst estimate for Neximmune Inc is for a
loss of 51 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Neximmune Inc
is $35, about 69.2% above its last closing price
of $10.78.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.67 -0.66 -0.71 Missed -7
This summary was machine generated August 6 at 20:32 GMT. All
figures in US dollars unless otherwise stated